High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer

British Journal of Cancer

Volumn 105, Issue 10, 2011, Pages 1480-1486

  Brain, E ^a   Levy, C ^b   Serin, D ^c   Roche H ^d   Spielmann, M ^e   Delva, R ^f   Veyret, C ^g   Mauriac, L ^h   Rios, M ⁱ   Martin, A L ^j   Jimenez, M ^j   Asselain, B ^a   Gauthier, M ^k   Bonnetain, F ^k   Fumoleau, P ^k  

^a INSTITUT CURIE   (France)

^b CENTRE FRANÇOIS BACLESSE   (France)

^c INSTITUT SAINTE CATHERINE   (France)

^d INSTITUT CLAUDIUS REGAUD   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f CENTRE PAUL PAPIN   (France)

^g CENTRE HENRI BECQUEREL   (France)

^h INSTITUT BERGONIÉ   (France)

ⁱ CENTRE ALEXIS VAUTRIN   (France)

^j FNCLCC   (France)

^k CENTRE GEORGES FRANÇOIS LECLERC   (France)

more..

Author keywords

adjuvant treatment; docetaxel; dose dense regimen; early breast cancer; skin toxicity; taxanes

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADJUVANT THERAPY; ADULT; AGED; ALOPECIA; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CONTROLLED STUDY; DERMATITIS; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ERYTHEMA; EXTERNAL BEAM RADIOTHERAPY; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HIGH RISK PATIENT; HUMAN; LIP EDEMA; MAJOR CLINICAL STUDY; MASTECTOMY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL TOXICITY; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; THERAPY DELAY; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED;

EID: 80755163619     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.414     Document Type: Article

References (21)

1. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 22: 4165-4174 (Pubitemid 46606185)
2. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, MArtino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP (2006) Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295: 1658-1667
3. Brain EGC, Bachelot T, Serin D, Kirscher S, Graic Y, Eymard JC, Extra JM, Combe M, Fourme E, Nogues C, Rouesse J (2005) Life-threatening sepsis associated with adjuvant adriamycin plus docetaxel for intermediate-risk breast cancer. J Am Med Assoc 293: 2367-2371 (Pubitemid 40676759)
4. Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, Ferree CR, Muss HB, Green MR, Norton L, Frei III E (1998) Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 90: 1205-1211 (Pubitemid 28407086)
5. Burnell M, Levine MN, Chapman JA, Bramwell V, Gelmon K, Walley B, Vandenberg T, Chalchal H, Albain KS, Perez EA, Rugo H, Pritchard K, O'Brien P, Shepherd LE (2010) Cyclophosphamide, epirubicin, and Fluorouracil vs dose-dense epirubicin and cyclophosphamide followed by Paclitaxel vs Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol 28: 77-82
6. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, MArtino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L (2003) Randomized trial of dose-dense vs conventionally scheduled and sequential vs concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21: 1431-1439 (Pubitemid 46594092)
7. Dang C, Hudis C (2006) Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg. Clin Breast Cancer 7: 51-58 (Pubitemid 43862835)
8. French Adjuvant Study Group (2001) Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 19: 602-611
9. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer. Ann Oncol 20: 1319-1329
10. Jacot W, Bibeau F, Gourgou-Bourgade S, Gutowski M, Colombo PE, Bleuse JP, Kramar A, Romieu G (2010) Phase II trial of dose dense docetaxel followed by FEC100 as neoadjuvant chemotherapy in patients with operable breast cancer. Am J Clin Oncol 33: 544-549
11. Jones RL, Walsh G, Ashley S, Chua S, Agarwal R, O'Brien M, Johnston S, Smith IE (2009) A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer. Br J Cancer 100: 305-310
12. Lambert-Falls R, Modugno S (2007) Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study. Clin Breast Cancer 7: 697-704 (Pubitemid 47344732)
13. Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Robert J, Ottaway J, Burnell M, Williams CK, Tu D (1998) Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, metho-trexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16: 2651-2658 (Pubitemid 28363028)
14. Levine MN, Whelan T (2006) Adjuvant chemotherapy for breast cancer-30 years later. N Engl J Med 355: 1920-1922 (Pubitemid 44664651)
15. Moebus V, Jackisch C, Lueck HJ, Du BA, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Schneeweiss A, Huober J, Harbeck N, von Minckwitz G, Runnebaum IB, Hinke A, Kreienberg R, Konecny GE, Untch M (2010) Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 28: 2874-2880
16. Norton L, Simon R (1977) Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 61: 1307-1317 (Pubitemid 8204100)
17. Norton L, Simon R, Brereton HD, Bogden AE (1976) Predicting the course of Gompertzian growth. Nature 264: 542-545
18. Robert N, Krekow L, Stokoe C, Clawson A, Iglesias J, O'Shaughnessy J (2011) Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study. Breast Cancer Res Treat 125: 115-120
19. Roché H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, Symann M, Kerbrat P, Soulie P, Eichler F, Viens P, Monnier A, Vindevoghel A, Campone M, Goudier MJ, Bonneterre J, Ferrero JM, Martin AL, Geneve J, Asselain B (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 24: 5664-5671 (Pubitemid 46631307)
20. Wildiers H, Dirix L, Neven P, Prove A, Clement P, Squifflet P, Amant F, Skacel T, Paridaens R (2009) Delivery of adjuvant sequential dose-dense FEC-Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Res Treat 114: 103-112
21. Yardley DA, Burris III HA, Farley CP, Barton JH, Peacock NW, Spigel DR, Greco FA, Hainsworth JD (2008) A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer. Clin Breast Cancer 8: 242-248 (Pubitemid 351962145)